Investor Relations Home
Download Documentation 2016 Guidance Worksheet
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation Update on ABP-700
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation ABP-700 & MDCO-216 Conference Call Presentation
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.14 (0.53%)
Data as of 12/08/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
11/29/17The Medicines Company Announces Definitive Agreement to Sell its Infectious Disease Business Unit to Melinta Therapeutics
—Transaction will significantly strengthen the Company’s financial position; expected to provide sufficient cash and liquidity to advance inclisiran through anticipated completion of pivotal trials and data readout in second half of 2019— —Transaction structure will provide potential to create additional value through robust royalty structure on future sales of antibiotic portfolio and ownership of Melinta common stock— PARSIPPANY, N.J... 
Printer Friendly Version
11/15/17The Medicines Company Names Dr. Fred Eshelman as Executive Chairman; Appoints Geno Germano to Its Board of Directors
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 15, 2017-- The Medicines Company (NASDAQ:MDCO) today announced that its Board of Directors has appointed Fredric N. Eshelman, PharmD., the Company’s current Chairman of the Board, to the newly created position of Executive Chairman, and Geno Germano, a pharmaceutical industry executive with over 30 years of leadership experience, as a new, independent Director of the Company. These appointments are effective ... 
Printer Friendly Version
11/06/17The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran
– Patient dosing commenced – – Comprehensive Phase III clinical program to assess LDL-C lowering and safety in a wide range of patients – – Efficient, focused and rapid program designed to support US and EU regulatory filings – PARSIPPANY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 6, 2017-- The Medicines Company (NASDAQ: MDCO) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced the initiation of the Phase ... 
Printer Friendly Version
10/25/17The Medicines Company Reports Third-Quarter 2017 Business and Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 25, 2017-- The Medicines Company (NASDAQ: MDCO) today reported its financial results for the third quarter ended September 30, 2017, and provided an update on its clinical and operational activities. “We made significant clinical and strategic progress during the third quarter,” said Clive Meanwell, M.D., Ph.D., Chief Executive Officer of The Medicines Company. “We aggressively advanced start-up work for th... 
Printer Friendly Version
Upcoming Events
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.